본문

  1. Home
366 Results:AA:MILLER L H 0.390 sec.
RSS 
다국어입력
 상세검색
 신착검색
선택출력 선택엑셀내보내기
21
Risk Protection, Service Use, and Health Outcomes under Colombia's Health Insurance Program for the Poor
Risk Protection, Service Use, and Health Outcomes under Colombia's Health Insurance Program for the Poor
Miller, G., | american economic association | 2013 ,
22
Quantitative trait loci modulate vertebral morphology and mechanical properties in a population of 18-month-old genetically heterogeneous mice
Quantitative trait loci modulate vertebral morphology and mechanical properties in a population of 18-month-old genetically heterogeneous mice
Reeves, G. M., | Elsevier Inc | 2007 ,
23
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis
Felsenberg, D., | Elsevier Inc | 2005 ,
24
Imaging bone microdamage in vivo with positron emission tomography
Imaging bone microdamage in vivo with positron emission tomography
Li, J., | Elsevier Inc | 2005 ,
25
Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa
Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa
Wojcik, M. H., | Elsevier Inc | 2010 ,
26
Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1–84
Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1–84
Miller, M. A., | Elsevier Inc | 2008 ,
27
Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa
Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa
Utz Andrea L,, | Elsevier Inc | 2008 ,
28
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss
McClung, M. R., | Elsevier Inc | 2009 ,
29
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
McClung, M., | Elsevier Inc | 2007 ,
30
Effects of daily treatment with parathyroid hormone 1–84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys
Effects of daily treatment with parathyroid hormone 1–84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys
Fox, J., | Elsevier Inc | 2007 ,
처음이전12345678910이후마지막